BCAL Diagnostics Limited

Equities

BDX

AU0000160921

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. Other stock markets 06:56:50 17/05/2024 BST			5-day change	1st Jan Change
0.105 ^AUD	-4.55%		+12.90%	+6.06%

03-06	BCAL Diagnostics Appoints CEO	MT
02-20	BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

BCAL Diagnostics Limited Announces Earnings Results for the Year Ended June 30, 2021

August 31, 2021 at 01:54 am

BCAL Diagnostics Limited announced earnings results for the year ended June 30, 2021. For the year, the company reported revenue from continuing operations of $275,252 against $442,096 a year ago. Total comprehensive loss for the year was $1,524,970 against $696,360 a year ago. Basic and diluted LPS from continuing operations was 1.13 cents against 0.61 year a year ago.

Latest news about BCAL Diagnostics Limited

BCAL Diagnostics Appoints CEO	03-05	MT
BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-20	CI
BCAL Diagnostics Joins Forces to Conduct Breast Cancer Blood Test Study in India	11-29	MT
BCAL Diagnostics Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Fall 5%	11-14	MT
BCAL Diagnostics Files for Additional Australian Patent Application	11-06	MT
BCAL Diagnostics Appoints COO	05/09/23	MT
Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023	04/09/23	CI
BCAL Diagnostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/08/23	CI
9,246,318 Ordinary Options of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023.	20/07/23	CI
54,752,379 Ordinary Shares of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023.	20/07/23	CI
BCAL Diagnostics Appoints Advisor	16/05/23	MT
Bcal Diagnostics Limited Opens New Laboratory in Sydney	04/05/23	CI
BCAL Diagnostics Opens Laboratory in Sydney	03/05/23	MT
BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23/02/23	CI
BCAL Diagnostics to Set Up Clinical Service Laboratory in Sydney	26/10/22	MT
BCAL Diagnostics Limited Announces Establishment of Development & Clinical Service Laboratory	24/10/22	CI
BCAL Diagnostics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	30/08/22	CI
BCAL Diagnostics Limited Enters US Product Development Agreement with Precion Inc	28/06/22	CI
20,596,692 Ordinary Shares of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 20-FEB-2022.	19/02/22	CI
BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2021	17/02/22	CI
Bcal Diagnostics Limited Provides Additional Information on Recent Analysis to Distinguish Between Blood Samples of Breast Cancer Patients and Normal Control Samples	08/02/22	CI
Bcal Diagnostics Limited Announces Recent Analysis Significantly Improves Commercial Prospects	06/02/22	CI
BCAL Diagnostics Names New CEO	11/01/22	MT
BCAL Diagnostics Limited Appoints John Hurrell as Chief Executive Officer, Effective 14 February 2022	10/01/22	CI
BCAL Diagnostics Limited Announces Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test	02/11/21	CI

Chart BCAL Diagnostics Limited

Duration

Period

More charts

Company Profile

BCAL Diagnostics Limited is an Australia-based biotechnology company, which is focused on improving health outcomes for women. The Companyâs principal activities include the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, including preparation for clinical trials. It developed a blood screening test to be used alongside breast cancer screening methods. The technology initially complements imaging technologies, such as the mammogram, while it further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location. Its BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring. The Company has partnered with Precion Inc. to optimize protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions.

Sector

Medical Equipment, Supplies & Distribution

Calendar

26/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BCAL DIAGNOSTICS LIMITED	+6.06%	18.53M
BIOMÉRIEUX	-4.67%	12.33B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-5.19%	8.14B
LANTHEUS HOLDINGS, INC.	+28.50%	5.62B
AUTOBIO DIAGNOSTICS CO., LTD.	-8.09%	4.24B
10X GENOMICS, INC.	-55.31%	3.06B
ANDON HEALTH CO., LTD.	+13.49%	2.76B
VITROLIFE AB	-1.34%	2.41B
MYRIAD GENETICS, INC.	+32.24%	2.23B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-3.55%	1.87B

Diagnostic & Testing Substances